CytomX Therapeutics, Inc.
CTMX
$2.03
$0.031.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.01% | 23.81% | 36.45% | 33.66% | 50.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.01% | 23.81% | 36.45% | 33.66% | 50.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.01% | 23.81% | 36.45% | 33.66% | 50.41% |
| SG&A Expenses | -3.77% | 5.39% | -0.97% | 6.94% | -8.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.94% | 3.00% | 5.02% | 16.85% | -5.29% |
| Operating Income | 653.67% | 232.15% | 485.49% | 185.09% | 114.05% |
| Income Before Tax | 219.88% | 104.35% | 865.75% | 304.68% | 135.70% |
| Income Tax Expenses | -93.79% | -94.01% | -94.27% | -56.43% | -- |
| Earnings from Continuing Operations | 332.83% | 151.64% | 5,700.88% | 235.84% | 126.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 332.83% | 151.64% | 5,700.88% | 235.84% | 126.25% |
| EBIT | 653.67% | 232.15% | 485.49% | 185.09% | 114.05% |
| EBITDA | 486.76% | 192.43% | 721.10% | 253.00% | 119.90% |
| EPS Basic | 301.66% | 141.21% | 2,103.17% | 204.26% | 121.64% |
| Normalized Basic EPS | 197.87% | 95.16% | 1,209.34% | 1,451.76% | 135.64% |
| EPS Diluted | 316.39% | 146.64% | 1,633.06% | 198.97% | 120.76% |
| Normalized Diluted EPS | 199.83% | 96.10% | 1,212.15% | 1,426.74% | 135.40% |
| Average Basic Shares Outstanding | 17.57% | 10.29% | 14.46% | 19.29% | 24.32% |
| Average Diluted Shares Outstanding | 17.30% | 10.03% | 14.60% | 19.43% | 24.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |